Logo image of ALVIO.PA

VALERIO TX (ALVIO.PA) Stock Price, Quote, News and Overview

EPA:ALVIO - Euronext Paris - Matif - FR0010095596 - Common Stock - Currency: EUR

0.0545  +0 (+2.83%)

ALVIO.PA Quote, Performance and Key Statistics

VALERIO TX

EPA:ALVIO (3/7/2025, 7:00:00 PM)

0.0545

+0 (+2.83%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High0.14
52 Week Low0.04
Market Cap8.41M
Shares154.36M
Float106.88M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO07-12 2005-07-12


ALVIO.PA short term performance overview.The bars show the price performance of ALVIO.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30

ALVIO.PA long term performance overview.The bars show the price performance of ALVIO.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of ALVIO.PA is 0.0545 EUR. In the past month the price increased by 1.3%. In the past year, price decreased by -50.68%.

VALERIO TX / ALVIO Daily stock chart

ALVIO.PA Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
4AB.DE ABBVIE INC 21.07 346.68B
1ABBV.MI ABBVIE INC 20.82 342.48B
AMG.DE AMGEN INC 16.43 161.21B
1AMGN.MI AMGEN INC 15.84 160.89B
1GILD.MI GILEAD SCIENCES INC 25.67 135.84B
GIS.DE GILEAD SCIENCES INC 25.39 134.40B
VX1.DE VERTEX PHARMACEUTICALS INC 1667.04 115.58B
ARGX.BR ARGENX SE 253.61 33.75B
22UA.DE BIONTECH SE-ADR N/A 24.36B
IDP.DE BIOGEN INC 9.25 20.54B
1BIIB.MI BIOGEN INC 8.39 19.21B
0QF.DE MODERNA INC N/A 13.19B

About ALVIO.PA

Company Profile

ALVIO logo image Valerio Therapeutics SA is a is a clinical-stage biotechnology company, which engages in the development of drugs for the treatment of orphan diseases. The company is headquartered in Paris, Ile-De-France and currently employs 38 full-time employees. The company went IPO on 2005-07-12. The firm targets tumor DNA functions through unparalleled mechanisms of action in the sought-after field of DNA damage response (DDR). The company aims at holding a portfolio of advanced programs targeting severe pathologies with unmet clinical needs. The company has two programs in clinical development stage: Livatag, a doxorubicin Transdrag in Phase III, for the treatment of primary liver cancer, and Validive, a clonidine Lauriad in Phase II, for treatment of radio/chemo-induced severe oral mucositis at patients with head and neck cancer. The company also has one registered product in the United States, Beleodaq/ belinostat, for the treatment of peripheral T-Cell lymphoma (PTCL) and opportunities for further development; and two initial drugs registered in Europe and the United States: Loramyc/ Oravig for the treatment of oropharyngeal candidiasis, and Sitavig for the treatment of recurring herpes labialis.

Company Info

VALERIO TX

49 boulevard du General Martial Valin

Paris ILE-DE-FRANCE FR

Employees: 38

Company Website: https://www.onxeo.com/

Investor Relations: http://www.onxeo.com/investors-en/

Phone: 33145587600

VALERIO TX / ALVIO.PA FAQ

What is the stock price of VALERIO TX today?

The current stock price of ALVIO.PA is 0.0545 EUR. The price increased by 2.83% in the last trading session.


What is the ticker symbol for VALERIO TX stock?

The exchange symbol of VALERIO TX is ALVIO and it is listed on the Euronext Paris - Matif exchange.


On which exchange is ALVIO.PA stock listed?

ALVIO.PA stock is listed on the Euronext Paris - Matif exchange.


What is the price forecast or stock price prediction for VALERIO TX stock?

7 analysts have analysed ALVIO.PA and the average price target is 0.01 EUR. This implies a price decrease of -81.28% is expected in the next year compared to the current price of 0.0545. Check the VALERIO TX stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is VALERIO TX worth?

VALERIO TX (ALVIO.PA) has a market capitalization of 8.41M EUR. This makes ALVIO.PA a Nano Cap stock.


How many employees does VALERIO TX have?

VALERIO TX (ALVIO.PA) currently has 38 employees.


What are the support and resistance levels for VALERIO TX (ALVIO.PA) stock?

VALERIO TX (ALVIO.PA) has a resistance level at 0.07. Check the full technical report for a detailed analysis of ALVIO.PA support and resistance levels.


Is VALERIO TX (ALVIO.PA) expected to grow?

The Revenue of VALERIO TX (ALVIO.PA) is expected to decline by -100% in the next year. Check the estimates tab for more information on the ALVIO.PA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy VALERIO TX (ALVIO.PA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does VALERIO TX (ALVIO.PA) stock pay dividends?

ALVIO.PA does not pay a dividend.


What is the Price/Earnings (PE) ratio of VALERIO TX (ALVIO.PA)?

VALERIO TX (ALVIO.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.12).


ALVIO.PA Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to ALVIO.PA. When comparing the yearly performance of all stocks, ALVIO.PA is a bad performer in the overall market: 97.57% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ALVIO.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to ALVIO.PA. ALVIO.PA may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ALVIO.PA Financial Highlights

Over the last trailing twelve months ALVIO.PA reported a non-GAAP Earnings per Share(EPS) of -0.12. The EPS increased by 31.63% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -67%
ROE -488.76%
Debt/Equity 2.88
Chartmill High Growth Momentum
EPS Q2Q%33.33%
Sales Q2Q%N/A
EPS 1Y (TTM)31.63%
Revenue 1Y (TTM)31.18%

ALVIO.PA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 34% to ALVIO.PA. The Buy consensus is the average rating of analysts ratings from 7 analysts.

For the next year, analysts expect an EPS growth of -136.11% and a revenue growth -100% for ALVIO.PA


Ownership
Inst Owners28.6%
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
Analysts
Analysts34.29
Price Target0.01 (-81.65%)
EPS Next Y-136.11%
Revenue Next Year-100%